Kornimate/medical-research-clean huggingface dataset:
cellular senescence and covid-19 long-hauler syndrome

Conditions: SARS-CoV2 Infection

Summary: the purpose of this study is to test if senescent cells and their secretome contribute to long-hauler syndrome and if a clinical trial of senolytic drugs, which selectively eliminate senescent cells, should be initiated.


Eligibility criteria:
longhauler's cohort - inclusion criteria: * ability to give informed consent or lar. * at least 18 years old. * ability of subject or lar to read and speak the english language. * positive pcr or antibody test within 12 months of initial study visit. * patient of the long-hauler syndrome clinic and differential diagnosis of long-hauler syndrome. exclusion criteria: * any potential participant who refuses medical record review. * pregnant females. * incarcerated individuals. * inability to cooperate or any medical condition that, in the opinion of the investigator, interferes with the evaluation of the study objectives or increases the subject's risk by participating in the study. control cohort - inclusion criteria: * ability to give informed consent * at least 18 years old * ability of subject to read and speak the english language exclusion criteria: * known case of covid-19. * any potential participant who refuses medical record review. * pregnant females. * incarcerated individuals. * inability to cooperate or any medical condition that interferes with the evaluation of the study objectives or increases the subject's risk by participating in the study. covid-19 control cohort inclusion criteria: * ability to give informed consent. * at least 18 years old. * ability of subject to read and speak the english language. * known case of covid-19. exclusion criteria: * known longhauler's syndrome/post-covid * any potential participant who refuses medical record review. * pregnant females. * incarcerated individuals. * inability to cooperate or any medical condition that interferes with the evaluation of the study objectives or increases the subject's risk by participating in the study.
repetitive intramyocardial cd34+ cell therapy in dilated cardiomyopathy (remedium)

Conditions: Dilated Cardiomyopathy; Heart Failure

Summary: the goal of remedium project is to develop personalized stem cell therapy for patients with chronic heart failure due to dilated cardiomyopathy (dcm). the main focus of the project is (1) on repetitive administration of cell therapy that would allow for long-lasting improvements in heart function and outcome in this patient population. in parallel, the investigators aim to (2) develop a standardized patient-specific stem cell product that could be cryopreserved and stored in a stem cell bank for prolonged time periods, and used for therapeutic application when clinically indicated. by using a unique multimodality imaging platform, the goal of this project is also to (3) define standardized clinical criteria that would serve as a guideline for evaluation of the effects of stem cell therapy in future clinical trials and everyday clinical settings. finally, to improve the clinical implementation of cell therapy,the investigators aim to (4) develop a stem cell delivery technique that could be used to treat both left and right and ventricular failure and could be implemented in a standardized fashion designed for a widespread clinical use.


Eligibility criteria:
inclusion criteria: * age 18-70 years old * diagnosis of dcm according to european society of cardiology position statement * left ventricular ejection fraction (lvef) by echocardiography 20-40%, * new york heart association (nyha) functional class heart failure ii or iii for at least 3 months before referral. exclusion criteria: * acute multi-organ failure * history of any malignant disease within 5 years * diminished functional capacity due to non-cardiac co-morbidities (copd, paod, morbid obesity) * pregnancy
quantification of fetal brains' sulci along gestation

Conditions: Fetal Brain Injury

Summary: gyrogenesis is an ontogenic process that transforms the smooth (lissencephalic) cortex toward its mature, convolved (gyrencephalic) state. a tortuous, branching and deepening pattern of sulci and fissures outlines for a well-developed cortex. the aim of this study is to find an algorithm that can detect the sulci in ultrasound images of fetus' brain and measure the length of it. this algorithm can be used for research demands like learning the development of the brain from embryo stages until the birth of the baby


Eligibility criteria:
inclusion criteria: * pregnant women between the ages of 18-35 * gestational age between 25-40 weeks * low risk pregnancies exclusion criteria: * multiple gestation * fetal brain abnormality
seocalcitol versus placebo in advanced hepatocellular carcinoma

Conditions: Liver Neoplasms

Summary: the purpose of the study is to determine whether seocalcitol is effective in the treatment of advanced primary liver cancer (hepatocellular carcinoma \[hcc\]).


Eligibility criteria:
inclusion criteria: * hospital in- or out-patients * either sex * aged 18-75 years * with hepatocellular carcinoma, verified by histology/cytology, which is not amenable to curative treatment or transplantation. * patients must have measurable disease, and be classifiable as to barcelona clinic liver cancer (bclc) stage 0, as described in llovet jm et al. hepatology 1999;29:62-67. exclusion criteria: * patients treated with chemotherapy or other anti-cancer therapy within 4 weeks before visit 1 * patients with another primary tumor, except for basocellular carcinoma of the skin or in situ carcinoma of the cervix, within the last 2 years * a history of renal stone(s) * a life expectancy of \< 3 months * world health organization (who) performance status 3 or 4 * okuda stage iii. * patients with hypercalcemia, or other clinically important laboratory abnormalities * patients with previous/current calcium metabolic disease, taking calcium-lowering therapy, or medication known to affect systemic calcium metabolism are also excluded. * all patients must give their signed informed consent to join the study.

Keywords: hepatocellular carcinoma liver cancer
preoperative methadone single dose reduces postoperative morphine consumption.

Conditions: Pain, Postoperative

Summary: the aim of this study was to evaluate the effect of intraoperative methadone on postoperative analgesic requirements, pain scores and patient satisfaction in comparison to standard intraoperative pain control with fentanyl.

patients of both genders and up to age 75 and asa classification iii were enrolled, when undergoing moderately to severely painful surgery scheduled for ≥90 minutes in general anaesthesia. patients were randomized to receive either a single shot of methadone (0.2mg/kg) or fentanyl (0.003mg/kg) for induction of anesthesia. in cases of insufficient intraoperative analgesia repeated fentanyl administration was possible. postoperative analgesia was provided with patient controlled morphine in both groups (pca = patient controlled analgesia). pain was assessed using the numerical rating scale (nrs) at rest and after coughing, at 15 minutes post extubation, and repeated every 6 hours up to 72 hours postoperatively. the levels of sedation and nausea/vomiting were also evaluated in parallel.

Eligibility criteria:
inclusion criteria: * informed consent * patients of both genders and up to age 75 and asa classification iii were enrolled, when undergoing moderately to severely painful surgery scheduled for ≥90 minutes in general anaesthesia. * german speaking patients exclusion criteria: * patients including other studies * pregnant * breast feeding * patients in methadone substitution therapy * dependent drug user * patients with bmi greater than 36kg/m2 * patients with chronic or acute renal failure with serum creatinine greater than 400µmol/l * patients with liver insufficiency or failure * alcoholics * patients with acute heard attack

Keywords: methadone postoperative pain acute pain therapy postoperative pain therapy
krt-232 in combination with tl-895 for the treatment of r/r mf and krt-232 for the treatment of jaki intolerant mf

Conditions: Myelofibrosis; Post-PV MF; Post-ET Myelofibrosis; Primary Myelofibrosis

Summary: this study evaluates krt-232 in combination with tl-895 for the treatment of relapsed or refractory myelofibrosis and krt-232 for the treatment of jak inhibitor intolerant myelofibrosis.

cohorts 1 and 2 will undergo dose finding and dose expansion. eligible patients will be randomly assigned to an open cohort, either cohort 1 or cohort 2. cohort 3 will be conducted as a dose expansion, independent of cohorts 1 and 2. cohort 1 will follow a 3+3 dose escalation design to determine the maximum tolerated dose (mtd)/maximum administered dose (mad) and recommended phase 2 dose (rp2d) of tl-895 administered qd in combination with krt-232. a safety review committee (src) will review the safety data during the dose escalation to decide on dose escalation and/or exploration of intermediate doses. cohort 2 will follow a 3+3 dose escalation design to determine the mtd/mad and recommended rp2d of tl-895 administered bid in combination with krt-232. an src will review the safety data during the dose escalation to decide on dose escalation and/or exploration of intermediate doses. cohort 3 will be conducted a 2-stage design. in stage 1, enrollment will continue until 15 evaluable patients have been enrolled. an src will review the data during the study and if there are ≥4 responders based on the futility criteria and safety data from stage 1, cohort 3 expansion will commence. if there are ≤3 patients responding to therapy, cohort 3 will be terminated. once expansion criteria have been met, cohort 3 will be expanded to a total of 46 evaluable patients for stage 2 analyses.

Eligibility criteria:
inclusion criteria: * confirmed diagnosis of primary mf, post-pv mf, or post-et mf, (who 2016) * ecog ≤ 2 * cohort 1 and cohort 2: r/r following jak inhibitor treatment * cohort 3: patients who are intolerant to jak inhibitor treatment exclusion criteria: * prior treatment with mdm2 inhibitors or p53-directed therapies * prior treatment with a bcr-abl, phosphoinositide 3-kinase (pi3k), mammalian target of rapamycin (mtor), bromodomain and extraterminal domain (bet), histone deacetylase (hdac), or spleen tyrosine kinase (syk) inhibitor * prior splenectomy * splenic irradiation within 3 months prior to the first dose of study treatment * clinically significant thrombosis within 3 months of screening * grade 2 or higher qtc prolongation

Keywords: relapsed/refractory myelofibrosis janus associated kinase inhibitor-intolerant myelofibrosis mdm2 navtemadlin
adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia

Conditions: Schizophrenia

Summary: hyperprolactinemia is a frequent consequence of treatment with typical antipsychotic agents and atypical antipsychotics such as risperidone. recent studies have suggested that aripiprazole, a partial dopamine agonist, reduces the prolactin response to antipsychotics. thus, we conducted this study to evaluate the dose effects of adjunctive treatment with aripiprazole on hyperprolactinemia in stable schizophrenic patients maintained with risperidone.


Eligibility criteria:
inclusion criteria: 1. aged 18-45 years of and fulfilled diagnostic and statistical manual of mental disorders(dsm-iv )criteria (american psychiatric association, 1994) for schizophrenia; 2. having a stable psychiatric condition, defined as taking the same dosage of risperidone for at least 6 weeks; 3. being treated with risperidone monotherapy; and presence of hyperprolactinemia associated with risperidone. exclusion criteria: 1. any other major psychiatric disorder; 2. significant concurrent medical illnesses, organic brain disorder, history of substance and alcohol abuse, and mental retardation

Keywords: risperidone; aripiprazole; hyperprolactinemia; dose effects
conventional versus automated measurement of blood pressure in the office (the cambo study)

Conditions: Hypertension

Summary: to determine if the use of automated office blood pressure readings can improve management of systolic hypertension in routine clinical practice. automated office sbp recordings in routine clinical practice using the bptru device will reflect more accurately the mean awake ambulatory systolic bp than will manual bp readings taken with conventional mercury sphygmomanometry. this should lead to improvements in the management of systolic hypertension with optimization of drug therapy in practices using the bptru device.


Eligibility criteria:
inclusion criteria: * both treated and untreated patients with systolic hypertension under routine fp care * for untreated patients, routine office sbp as measured by the patient's fp at the last routine office visit using a mercury device must have sbp ≥ 160 mmhg and dbp \<= 95 mmhg * for patients already receiving antihypertensive therapy, the last routine office bp as measured by the patient's fp using mercury sphygmomanometry must be sbp ≥ 140 mmhg and dbp \<= 90 mmhg exclusion criteria: * presence of target organ damage such as mi, stroke, and serum creatinine twice normal * diabetes mellitus treated with insulin or oral hypoglycemic therapy * secondary hypertension * participation in another research study involving measurement of bp * patient's insistence on using self bp measurement outside of the study * any conditions or circumstances which might preclude the successful completion of the study

Keywords: hypertension blood pressure systolic pressure diastolic pressure blood pressure monitoring, ambulatory
weighted blanket to treat anxiety related to trying new foods the pediatric population

Conditions: Food Neophobia; Picky Eating; Avoidant Restrictive Food Intake Disorder; Anxiety State

Summary: this small experimental pilot study addresses the knowledge gap related to the use of weighted blankets for children with anxiety related to food and eating.

the purpose of the study is to research if weighted blankets might help children with anxiety related to food tolerate new foods better. the parent will be asked to complete a 10-question questionnaire and make a list of the foods the child eats on three occasions (before the study begins, after a control period and after the child uses the weighted blanket). the child will be asked to use a weighted blanket for 5 to 15 minutes prior to at least 3 meals a week for one month, and the child will be asked to complete a 20-question questionnaire taking about 5-12 minutes to complete asking about how they feel on days that they use the weighted blanket and one time a week during the month that they don't use the weighted blanket. the parent will be asked to report any new foods the child tries on the days that they do use the weighted blanket. the parent will be asked to keep the weighted blanket and supervise all use of the weighted blanket for safety. this study will take approximately 2 months total.

Eligibility criteria:
inclusion criteria: 1. subject and guardian has provided informed consent in a manner approved by the irb and is willing and able to comply with the trial procedures. 2. subject has identified feeding challenges 3. subject has anxiety related to food as reported by caregiver 4. subject is between the ages of 8-12 5. subject has good reading abilities 6. subject weighs 30 pounds or more exclusion criteria: 1. any medical condition that, in the opinion of the investigator, would place the subject at increased risk for participation due to the inability to remove the blanket safely. examples of diagnoses that would exclude a participant include spinal cord injury, cerebral palsy, and muscular dystrophy. 2. concurrent participation on another research study 3. participants outside of the ages 8-12 4. participants refuse to use the weighted blanket 5. if the use of a weighted blanket is contraindicated for any reason 6. participants lacking the reading ability to complete a questionnaire 7. participants who weigh under 30 pounds per parent report and cannot use a commercially available weighted blanket as the minimum weight of a weighted blanket is 3 pounds will be excluded but this exclusion is unlikely due to the inclusion age range

Keywords: weighted blanket food avoidance picky eater state anxiety anxiety related to food children
immune profiling for cancer immunotherapy response

Conditions: Cancer; Tumor, Solid; Hematologic Malignancy; Blood Cancer

Summary: in patients clinically treated with fda-approved immunotherapy the investigators will assess the predictive value of pre- and on-treatment 1) immune-methylation profiling across cancer types, and 2) immune-methylation profiling and cytokine profiling within cancer types.


Eligibility criteria:
inclusion criteria: * cancer patients receiving or will receive immunotherapy under fda- approved indication (e.g. checkpoint inhibitor therapy with pembrolizumab, nivolumab, or ipilimumab, or cellular immunotherapy). * participants are eligible regardless of the type of prior therapy (i.e. prior immunotherapy treated participants can be included). exclusion criteria: * pregnant women/fetuses/neonates * prisoners * decision-impaired individuals

Keywords: immunotherapy
mesenchymal stromal cell therapy in patients with chronic myocardial ischemia (mystromalcell trial)

Conditions: Chronic Ischemic Heart Disease

Summary: coronary artery disease (cad) is the most common cause of death and a major cause of hospital admissions for acute chest pain. in spite of improved treatments still many patients with cad have daily attacks of severe chest pain and severely reduced life quality. the investigators have established a double-blind placebo-controlled trial in patients with cad to test efficacy and safety of treatment with adipose derived stem cells to improve perfusion in the heart muscle and exercise capacity, and reduce the patient's symptoms.

in an open single centre pilot study we have evaluated the safety and efficacy of msc treatment to improve heart muscle perfusion in patients with chronic cad. patients treated with mscs had significant increased exercise capacity, reduction in angina, angina attacks and medication and in life quality at 6 months follow-up. for all the parameters there was a tendency towards improved outcome with increasing number of cells. the treatment with mscs was safe. the investigators have now established a double-blind placebo-controlled trial in patients with cad to test efficacy and safety of treatment with mscs to improve perfusion in the heart muscle and exercise capacity, and reduce the patient's symptoms.

Eligibility criteria:
inclusion criteria: * ccs iii - iv * coronary artery stenosis/occlusion not treatable with invasive procedures * lvef \> 40% * ett between 2 - 10 min exclusion criteria: * valvular heart disease * fev1 \< 1 * severe systemic disease * acute coronary syndrome \> 2 months

Keywords: patients
evaluations of the effects of tranexamic acid and chlorhexidine gel on alveolar osteitis incidence

Conditions: Alveolar Osteitis

Summary: this intervention is the treatment of alveolar osteitis (alveolitis) with different effects, which occurs due to the formation of clot after extraction, which is one of the most common intervals after tooth extraction.98 healthy patients with molar and premolar teeth with indication for extraction were taken to the recep tayyip erdoğan university faculty of dentistry, department of oral and maxillofacial diseases and surgery clinic between may 2024 and june 2024 (age: 38 sessions: 19). -62) 113 teeth (85 molar, 28 premolar teeth) were treated with spongostan placed in the tooth socket after extraction, spongostan with chlorhexidine gel and spongostan with tranexamic acid, randomly distributed. after extraction, alveolitis was observed and evaluated prospectively using spongostan, chlorhexidine gel and tranexamic acid in the dental sockets. the researcher checked the participants on the 3rd and 7th days after the tooth extraction. the researcher recorded the pain and edema levels by asking the participants between 0 and 10 using the visual analogue scale (vas). the researcher filled in the forms for the presence of halitosis, trismus and exposed bone socket on the 3rd and 7th days (yes-no). permanent analyzes of the study were created with the spss package program.


Eligibility criteria:
inclusion criteria: 1. healthy individuals between the ages of 18-65 2. molar and premolar teeth with extraction indication exclusion criteria: 1. against drugs or substances to be used in surgery (articaine, tranexamic acid, chlorhexidine) have allergies, 2. those who used antibiotics 30 days before the dental extraction, 3. clinical and radiological examinations in the operation area 30 days before dental extraction and/or on the day of the procedure. any signs of pathology and infection (such as periapical pathology, pericoronitis), 4. those who routinely use oral antiseptics, 5. systemic fever, absence of growth such as lymphadenopathy (lap), 6. women are lactating or pregnant, 7. using oral contraceptives, 8. procedures that were not attended to control appointments (day 3-7) were not included.

Keywords: alveolar osteitis
ml-based multi-sensor fall risk screening in dmd

Conditions: DMD

Summary: this prospective observational study aims to analyze changes in upper extremity functional movement over time in children with duchenne muscular dystrophy (dmd). thirty patients will be evaluated at three time points (baseline, 6 months, 12 months) using clinical assessments (pul 2.0, brooke scale, grip strength), computer vision-based video analysis, and machine learning algorithms. the goal is to improve future upper limb evaluation methods for non-ambulatory dmd patients. the study includes safety monitoring and adheres to ethical standards, ensuring patient data confidentiality and providing compensation if adverse effects occur.


Eligibility criteria:
inclusion criteria: 1. individuals with a confirmed genetic diagnosis of duchenne muscular dystrophy (dmd) 2. age over 10 and under 30 years 3. brooke scale score between 2 and 5 4. manual muscle test grade below 3 for shoulder abduction muscles exclusion criteria: 1. individuals who are unable or unwilling to provide informed consent 2. brooke scale score of 1 or 6 3. individuals with cognitive impairments that significantly limit their ability to participate in assessments
gr defect in peripheral blood mononuclear cells in copd

Conditions: Chronic Obstructive Pulmonary Disease

Summary: t.to investigate a possible mechanism of the glucocorticosteroid receptors (gr) defect in patients with severe copd by studying the effect of dexamethasone (dex) on gr- binding, interleukin production (il-6/il-8) and mkp-1 expression in peripheral blood mononuclear cells blood (pbmc)


Eligibility criteria:
inclusion criteria: * patients with severe (stage iii, gold) to very severe (stage iv, gold) copd or subjects who are healthy smokers or subjects who are non-smokers * written informed consent exclusion criteria: * current upper respiratory tract infections * any significant disease or disorder (e.g. cardiovascular, pulmonary (other than asthma), gastrointestinal, liver, renal, neurological, musculoskeletal, endocrine, metabolic, malignant, psychiatric, major physical impairment) which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or may influence the results of the study, or the subjects ability to participate in the study * subjects not considered capable, as judged by the investigator, of following instructions of the study, e.g. because of a history of alcohol or drug abuse or any other reason